Akebia Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -12.34%
- Market cap
- $138.50M
- 277.66M shares
- Filings
- 887
Q3 2026+47.5% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+256.4% FY25 yoy
- $138.50M
- —
- 0.7×
- 6.8×
- 10.01%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $236,196,000 | reported | |
| FY 2024 | 2024-12-31 | $160,180,000 | reported | |
| FY 2023 | 2023-12-31 | $194,623,000 | reported | |
| FY 2022 | 2022-12-31 | $292,484,000 revised | reported | |
| FY 2021 | 2021-12-31 | $211,650,000 revised | reported | |
| FY 2020 | 2020-12-31 | $294,644,000 revised | reported | |
| FY 2019 | 2019-12-31 | $335,001,000 | reported | |
| FY 2018 | 2018-12-31 | $207,742,000 | reported | |
| FY 2017 | 2017-12-31 | $181,227,000 | reported | |
| FY 2016 | 2016-12-31 | $1,535,000 | reported | |
| FY 2015 | 2015-12-31 | $0 | reported | |
| FY 2014 | 2014-12-31 | $0 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2014 | — | $162.00K | $162.00K | — | 20.37M sh | +1,372.6% | — |
Segments
Products
LineFY2025ShareChange
Product revenue, net$227.33M96%+49.4%
Auryxia$181.54M77%+19.3%
Vafseo$45.79M19%—
License, collaboration and other revenue$8.86M3.8%+10.8%
Total$236.20M
Pharmaceutical preparations
Akebia Therapeutics, Inc. is the 79th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
SDGRSchrodinger, Inc.$255.9M23.3%40.4%$2.3BRCUSArcus Biosciences, Inc.$247.0M4.3%142.9%$2.6BKROSKeros Therapeutics, Inc.$244.1M6,775.0%35.7%$197.2M
AKBAAkebia Therapeutics, Inc. (this company)$236.2M47.5%2.3%$138.5M
ANABAnaptysbio, Inc$234.6M157.0%5.6%$1.4BPBYIPuma Biotechnology, Inc.$228.4M0.9%13.6%$418.0MIDYAIDEAYA Biosciences, Inc.$218.7M3,024.4%52.0%$3.0BVNDAVanda Pharmaceuticals Inc.$216.1M8.7%102.0%$238.9MAMRNAmarin Corp Plcuk$213.6M6.5%18.2%$4.9BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Akebia Therapeutics, Inc. · CIK 1517022 · Engraved from SEC EDGAR